Strongbridge Bio Ord (SBBP) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SBBP

2
+0.03 (+1.52%)
At close: Oct 5, 2021
2.02
+0.02 (+1%)
After Hours: 10/5/2021, 8:21:57 PM
Fundamental Rating

3

Overall SBBP gets a fundamental rating of 3 out of 10. We evaluated SBBP against 191 industry peers in the Pharmaceuticals industry. SBBP may be in some trouble as it scores bad on both profitability and health. SBBP is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year SBBP has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -41.48%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -124.18%
PM (TTM) -115.66%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • There is no outstanding debt for SBBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

  • Based on the Altman-Z score of -3.75, we must say that SBBP is in the distress zone and has some risk of bankruptcy.
  • A Debt/Equity ratio of 0.38 indicates that SBBP is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Altman-Z -3.75
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

  • SBBP has a Current Ratio of 3.00. This indicates that SBBP is financially healthy and has no problem in meeting its short term obligations.
  • SBBP has a Quick Ratio of 2.95. This indicates that SBBP is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 3
Quick Ratio 2.95

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 49.38% over the past year.
  • The Revenue has grown by 34.98% in the past year. This is a very strong growth!
  • SBBP shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 63.38% yearly.
EPS 1Y (TTM)49.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
Revenue 1Y (TTM)34.98%
Revenue growth 3Y63.38%
Revenue growth 5YN/A
Sales Q2Q%29.41%

3.2 Future

  • SBBP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.82% yearly.
  • SBBP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 45.58% yearly.
EPS Next Y35.78%
EPS Next 2Y29.57%
EPS Next 3Y42.71%
EPS Next 5Y34.82%
Revenue Next Year25.01%
Revenue Next 2Y38.84%
Revenue Next 3Y42.39%
Revenue Next 5Y45.58%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SBBP Yearly Revenue VS EstimatesSBBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
SBBP Yearly EPS VS EstimatesSBBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • SBBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SBBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SBBP Price Earnings VS Forward Price EarningsSBBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -2.36
SBBP Per share dataSBBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SBBP's earnings are expected to grow with 42.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.57%
EPS Next 3Y42.71%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SBBP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

Strongbridge Bio Ord

NASDAQ:SBBP (10/5/2021, 8:21:57 PM)

After market: 2.02 +0.02 (+1%)

2

+0.03 (+1.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04
Earnings (Next)03-02
Inst Owners0.02%
Inst Owner Change0%
Ins Owners6.77%
Ins Owner Change0%
Market Cap135.66M
Revenue(TTM)34.72M
Net Income(TTM)-40.16M
Analysts80
Price Target5.1 (155%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.91
P/FCF N/A
P/OCF N/A
P/B 3.06
P/tB N/A
EV/EBITDA -2.36
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.51
BVpS0.65
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.48%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -124.18%
PM (TTM) -115.66%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3
Quick Ratio 2.95
Altman-Z -3.75
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
EPS Next Y35.78%
EPS Next 2Y29.57%
EPS Next 3Y42.71%
EPS Next 5Y34.82%
Revenue 1Y (TTM)34.98%
Revenue growth 3Y63.38%
Revenue growth 5YN/A
Sales Q2Q%29.41%
Revenue Next Year25.01%
Revenue Next 2Y38.84%
Revenue Next 3Y42.39%
Revenue Next 5Y45.58%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Strongbridge Bio Ord / SBBP FAQ

What is the fundamental rating for SBBP stock?

ChartMill assigns a fundamental rating of 4 / 10 to SBBP.


Can you provide the valuation status for Strongbridge Bio Ord?

ChartMill assigns a valuation rating of 1 / 10 to Strongbridge Bio Ord (SBBP). This can be considered as Overvalued.


How profitable is Strongbridge Bio Ord (SBBP) stock?

Strongbridge Bio Ord (SBBP) has a profitability rating of 2 / 10.


How financially healthy is Strongbridge Bio Ord?

The financial health rating of Strongbridge Bio Ord (SBBP) is 3 / 10.


What is the earnings growth outlook for Strongbridge Bio Ord?

The Earnings per Share (EPS) of Strongbridge Bio Ord (SBBP) is expected to grow by 35.78% in the next year.